Live Breaking News & Updates on Assessment In Spondyloarthritis International Society

Stay updated with breaking news from Assessment in spondyloarthritis international society. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis

/PRNewswire/ AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active. ....

Michael Severino , European Commission , Drug Administration , Exchange Commission , Assessment In Spondyloarthritis International Society , Abbvie Deutschland Gmbh Co , Spondyloarthritis International Society , Ankylosing Spondylitis , Disease Activity , Low Disease Activity , Efficacy Results , Magnetic Resonance Imaging , Total Back , Axial Spondyloarthritis , Important Safety Information About , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Psoriatic Arthritis , Inadequate Response , Week Data , Randomized Controlled Phase , Vie Deutschland Gmbh , Evaluate Efficacy , Adult Participants With Axial Spondyloarthritis , Maintenance Therapy ,

Pfizer reports fourth-quarter and full-year 2020 results and releases 5-YEAR pipeline metrics

5%
Below are specific updates on pipeline assets since our previous earnings announcement on October 27, 2020:
Abrocitinib (PF-04965842) In November 2020, Pfizer announced positive top-line results from the fifth Phase 3 trial of abrocitinib, JADE REGIMEN, a 52-week study which investigated abrocitinib in patients 12 and older with moderate to severe atopic dermatitis (AD) following response to initial open label induction treatment with abrocitinib 200 mg. Patients were randomized into one of three arms: 200 mg, 100 mg or placebo. Both doses of abrocitinib met the primary endpoint, resulting in significantly fewer patients experiencing a loss of response requiring rescue treatment compared to those randomized to placebo. Both doses also met the key secondary endpoint of a larger percentage of patients maintaining an Investigator’s Global Assessment (IGA) response of clear or almost clear relative to placebo. ....

South Africa , Comunidad Autonoma De Cataluna , South African , Frank Damelio , Mylannv Mylan , Valneva Lyme , Vyndaqel Vyndamax , Albert Bourla , Eli Lilly , Upjohn Inc , Health Inc , Sangamo Therapeutics Inc , Merck Co Inc , Merck Kga , Pfizer Inc , Abbvie Inc , Drug Administration , European Commission , Myovant Sciences , Business Development , Bristol Myers Squibb Company , Gilead Sciences Inc , Johnson Corporation , Assessment In Spondyloarthritis International Society , European Union , Research Developments ,